Thailand, Dec. 4, 2025 — Xiamen Innovax Biotech Co., Ltd. (INNOVAX) and Thailand’s National Vaccine Institute (NVI) jointly served as witnesses to Global Biotech Products Co., Ltd. (GBP) being awarded the Thailand Triple S Awards 2025 (Science, Society and Sustainability) by the Thailand Science Research and Innovation Agency (TSRI), an honor unveiled as part of the Thailand SRI Index 2025. This milestone recognizes the joint efforts of INNOVAX and GBP in the 9-valent HPV vaccine technology-transfer project, with strong support from NVI.

GBP’s accolade is rooted in its innovative collaboration with INNOVAX on the 9-valent HPV vaccine technology transfer, supported by NVI. This partnership has significantly strengthened Thailand’s long-term vaccine supply security, enhanced domestic manufacturing capacity, and laid the groundwork for a more resilient national public health infrastructure.

As the original technology provider of the 9-valent HPV vaccine, INNOVAX is trusted to contribute to this initiative supported by NVI, working alongside GBP as a dedicated manufacturing partner. The two parties, with NVI’s support, continue to drive Thailand’s sustainable vaccine development through comprehensive technology transfer, capacity building, and knowledge sharing initiatives.

INNOVAX once again extends its heartfelt congratulations to GBP on this prestigious national recognition. The company looks forward to deepening its cooperation with GBP — with NVI’s support — to further advance vaccine innovation in Thailand and bolster the country’s self-sufficiency in vaccine supply.

About HPV 9v Localization in Thailand Between Innovax & GBP

In July 2024, INNOVAX inked a long-term cooperation agreement with GBP for the technology transfer of the 9-valent HPV vaccine, with the initiative supported by Thailand’s National Vaccine Institute (NVI). Under this partnership, INNOVAX not only supplies 9-valent adsorbed bulk of the HPV vaccine to GBP but also provides a full suite of technical packages covering analytical method transfer, process transfer and process validation, coupled with systematic personnel training. For any experimental challenges GBP encounters, INNOVAX’s technical experts conduct on-site visits to diagnose root causes and offer hands-on solutions until issues are fully resolved. This collaboration is designed to enable GBP to realize localized production, registration and commercialization of the 9-valent HPV vaccine in Thailand. As INNOVAX’s CEO noted, “As public health products, vaccines should be equally accessible to all people. We understand and support each country in its robust supply of vaccines to its people. That's why we are open to vaccine technology transfer.” GBP has also commented that while others keep technology locked away, INNOVAX has handed over the “key to decryption”, truly helping Thailand move toward vaccine self-sufficiency.